search
Back to results

Placement of Covered Stents to Treat Hemodialysis Access Stenoses in the Cephalic Arch and Central Veins

Primary Purpose

Hemodialysis

Status
Unknown status
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
PTA alone without use of the GORE VIABAHN
GORE VIABAHN® Endoprosthesis with Heparin Bioactive Surface
Sponsored by
American Access Care
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Hemodialysis focused on measuring Hemodialysis, Fistula, Angiograph, Angiogram, Adult patients who are currently receiving hemodialysis treatment via an AV vascular graft or fistula located in the upper extremity

Eligibility Criteria

18 Years - 70 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Hemodialysis patient with a mature forearm or upper arm access that was created > 2 months before enrollment in study.
  2. The patient is ≥ 18 years of age.
  3. The patient has a reasonable expectation of remaining on hemodialysis for 12 months.
  4. The patient or his/her legal guardian understands the study and is willing and able to comply with follow-up requirements.
  5. The patient or his/her legal guardian is willing to provide informed consent.
  6. The patient has lesions that meet the angiographic inclusion / exclusion criteria and induce clinical, hemodynamic or functional abnormality.

Exclusion Criteria:

  1. The patient has a known or suspected systemic infection.
  2. The patient has a known or suspected infection of the hemodialysis access and / or bacteremia.
  3. The patient is currently taking maintenance immunosuppressant medication such as rapamycin, mycophenolate or mycophenolic acid, prednisone (>10 mg per day), cyclosporine, tacrolimus, or cyclophosphamide.
  4. The patient has known bleeding disorder (e.g., hemophilia or von Willebrand's disease).
  5. The patient has known sensitivity to heparin.
  6. The patient is scheduled for a live donor kidney transplant.
  7. The patient is enrolled in another investigational study or another access maintenance trial
  8. The patient has comorbid conditions that may limit their ability to comply with the follow-up requirements
  9. Life expectancy is ≤ 24 months.
  10. The patient has an untreatable allergy to radiographic contrast material.
  11. The patient is pregnant.
  12. In the opinion of the operating physician, the patient's hemodialysis access circuit is unsuitable for endovascular treatment.
  13. The patient's access is planned to be abandoned within 1 year.
  14. The patient has indwelling catheters (dialysis, pacemakers, ports).
  15. The patient has a central vein stent that would lead to jailing of the internal jugular vein.
  16. The patient experiences angioplasty-induced venous rupture.
  17. The patient has a flow limiting dissection after angioplasty.
  18. The patient's hemodialysis access is thrombosed.

Sites / Locations

  • American Access Care of BronxRecruiting
  • American Access Care of QueensRecruiting
  • Access Care Physicians of New YorkRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Experimental

Arm Label

Percutaneous Transluminal Angioplasty (PTA) alone

PTA with covered stent

Arm Description

Intervention: Procedure: PTA alone without use of the GORE VIABAHN

GORE VIABAHN® Endoprosthesis with Heparin Bioactive Surface

Outcomes

Primary Outcome Measures

Primary patency at 3, 6, and 12 months
Target lesion primary patency at 3, 6, and 12 months

Secondary Outcome Measures

Secondary patency at 3, 6, and 12 months
Target lesion secondary patency at 3, 6, and 12 months, access circuit primary and secondary patency at 3, 6, and 12 months, anatomic, clinical, and procedural success. Adverse events through 1 month

Full Information

First Posted
December 1, 2010
Last Updated
January 6, 2011
Sponsor
American Access Care
search

1. Study Identification

Unique Protocol Identification Number
NCT01271881
Brief Title
Placement of Covered Stents to Treat Hemodialysis Access Stenoses in the Cephalic Arch and Central Veins
Official Title
Placement of Covered Stents to Treat Hemodialysis Access Stenoses in the Cephalic Arch and Central Veins
Study Type
Interventional

2. Study Status

Record Verification Date
January 2011
Overall Recruitment Status
Unknown status
Study Start Date
October 2010 (undefined)
Primary Completion Date
October 2011 (Anticipated)
Study Completion Date
undefined (undefined)

3. Sponsor/Collaborators

Name of the Sponsor
American Access Care

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Balloon angioplasty is used to open up a narrowing that forms in hemodialysis fistula. Two areas of particular problems are the terminal portion of the cephalic vein near the shoulder and the central veins in the chest. Although angioplasty is standard of care the treated narrowed segments of vein mostly renarrow within 3 months requiring retreatment to keep your dialysis access functional. Recently there has been introduction of a new technology called a covered stent graft. Initial studies suggest that placing this device across the area of narrowing leads to dialysis access staying open longer and needing less angioplasty treatments. This study is designed to compare angioplasty (standard of care) versus using a covered stent graft. The investigators will then look at the dialysis records and future fistulograms to see if there is decreased flow through the fistula at 3, 6 and 12 months after the initial procedure.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hemodialysis
Keywords
Hemodialysis, Fistula, Angiograph, Angiogram, Adult patients who are currently receiving hemodialysis treatment via an AV vascular graft or fistula located in the upper extremity

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
140 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Percutaneous Transluminal Angioplasty (PTA) alone
Arm Type
Active Comparator
Arm Description
Intervention: Procedure: PTA alone without use of the GORE VIABAHN
Arm Title
PTA with covered stent
Arm Type
Experimental
Arm Description
GORE VIABAHN® Endoprosthesis with Heparin Bioactive Surface
Intervention Type
Other
Intervention Name(s)
PTA alone without use of the GORE VIABAHN
Intervention Description
PTA alone with no stent used
Intervention Type
Device
Intervention Name(s)
GORE VIABAHN® Endoprosthesis with Heparin Bioactive Surface
Other Intervention Name(s)
Covered stent
Intervention Description
Covered stent produced by GORE VIABAHN
Primary Outcome Measure Information:
Title
Primary patency at 3, 6, and 12 months
Description
Target lesion primary patency at 3, 6, and 12 months
Time Frame
1 year
Secondary Outcome Measure Information:
Title
Secondary patency at 3, 6, and 12 months
Description
Target lesion secondary patency at 3, 6, and 12 months, access circuit primary and secondary patency at 3, 6, and 12 months, anatomic, clinical, and procedural success. Adverse events through 1 month
Time Frame
1 year

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Hemodialysis patient with a mature forearm or upper arm access that was created > 2 months before enrollment in study. The patient is ≥ 18 years of age. The patient has a reasonable expectation of remaining on hemodialysis for 12 months. The patient or his/her legal guardian understands the study and is willing and able to comply with follow-up requirements. The patient or his/her legal guardian is willing to provide informed consent. The patient has lesions that meet the angiographic inclusion / exclusion criteria and induce clinical, hemodynamic or functional abnormality. Exclusion Criteria: The patient has a known or suspected systemic infection. The patient has a known or suspected infection of the hemodialysis access and / or bacteremia. The patient is currently taking maintenance immunosuppressant medication such as rapamycin, mycophenolate or mycophenolic acid, prednisone (>10 mg per day), cyclosporine, tacrolimus, or cyclophosphamide. The patient has known bleeding disorder (e.g., hemophilia or von Willebrand's disease). The patient has known sensitivity to heparin. The patient is scheduled for a live donor kidney transplant. The patient is enrolled in another investigational study or another access maintenance trial The patient has comorbid conditions that may limit their ability to comply with the follow-up requirements Life expectancy is ≤ 24 months. The patient has an untreatable allergy to radiographic contrast material. The patient is pregnant. In the opinion of the operating physician, the patient's hemodialysis access circuit is unsuitable for endovascular treatment. The patient's access is planned to be abandoned within 1 year. The patient has indwelling catheters (dialysis, pacemakers, ports). The patient has a central vein stent that would lead to jailing of the internal jugular vein. The patient experiences angioplasty-induced venous rupture. The patient has a flow limiting dissection after angioplasty. The patient's hemodialysis access is thrombosed.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Abigail Falk, Dr.
Phone
914-683-9731
Email
abigailfalk123@pol.net
First Name & Middle Initial & Last Name or Official Title & Degree
Claudio Cantu, RPA
Phone
914-683-9729
Email
CCantu@aac-llc.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Abigail Falk, Dr.
Organizational Affiliation
American Access Care Physician
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Claudio Cantu, RPA
Organizational Affiliation
American Access Care Center Operations Manager
Official's Role
Study Chair
Facility Information:
Facility Name
American Access Care of Bronx
City
Bronx
State/Province
New York
ZIP/Postal Code
10461
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Abigail Falk, Dr.
Phone
718-794-9729
Email
abigailfalk123@pol.net
First Name & Middle Initial & Last Name & Degree
Abigail Falk, Dr.
Facility Name
American Access Care of Queens
City
Flushing
State/Province
New York
ZIP/Postal Code
11366
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Kiran Jotwani, MD
Phone
718-820-9729
First Name & Middle Initial & Last Name & Degree
Kiran Jotwani, MD
Facility Name
Access Care Physicians of New York
City
White Plains
State/Province
New York
ZIP/Postal Code
10601
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Claudio Cantu, RPA
Phone
914-683-9729
Email
CCacntu@aac-llc.com
First Name & Middle Initial & Last Name & Degree
Claudio Cantu, RPA

12. IPD Sharing Statement

Citations:
PubMed Identifier
10584659
Citation
Gray RJ, Sacks D, Martin LG, Trerotola SO. Reporting standards for percutaneous interventions in dialysis access. Technology Assessment Committee. J Vasc Interv Radiol. 1999 Nov-Dec;10(10):1405-15. doi: 10.1016/s1051-0443(99)70252-6. No abstract available.
Results Reference
background
PubMed Identifier
11877717
Citation
Sidawy AN, Gray R, Besarab A, Henry M, Ascher E, Silva M Jr, Miller A, Scher L, Trerotola S, Gregory RT, Rutherford RB, Kent KC. Recommended standards for reports dealing with arteriovenous hemodialysis accesses. J Vasc Surg. 2002 Mar;35(3):603-10. doi: 10.1067/mva.2002.122025.
Results Reference
background
PubMed Identifier
14712430
Citation
Chang CJ, Ko PJ, Hsu LA, Ko YS, Ko YL, Chen CF, Huang CC, Hsu TS, Lee YS, Pang JH. Highly increased cell proliferation activity in the restenotic hemodialysis vascular access after percutaneous transluminal angioplasty: implication in prevention of restenosis. Am J Kidney Dis. 2004 Jan;43(1):74-84. doi: 10.1053/j.ajkd.2003.09.015.
Results Reference
background
PubMed Identifier
9807560
Citation
Patel RI, Peck SH, Cooper SG, Epstein DM, Sofocleous CT, Schur I, Falk A. Patency of Wallstents placed across the venous anastomosis of hemodialysis grafts after percutaneous recanalization. Radiology. 1998 Nov;209(2):365-70. doi: 10.1148/radiology.209.2.9807560.
Results Reference
background
PubMed Identifier
14562971
Citation
Rajan DK, Clark TW. Patency of Wallstents placed at the venous anastomosis of dialysis grafts for salvage of angioplasty-induced rupture. Cardiovasc Intervent Radiol. 2003 May-Jun;26(3):242-5. doi: 10.1007/s00270-003-2706-x.
Results Reference
background
PubMed Identifier
10405739
Citation
Haage P, Vorwerk D, Piroth W, Schuermann K, Guenther RW. Treatment of hemodialysis-related central venous stenosis or occlusion: results of primary Wallstent placement and follow-up in 50 patients. Radiology. 1999 Jul;212(1):175-80. doi: 10.1148/radiology.212.1.r99jl21175.
Results Reference
background
PubMed Identifier
15466790
Citation
Vogel PM, Parise C. SMART stent for salvage of hemodialysis access grafts. J Vasc Interv Radiol. 2004 Oct;15(10):1051-60. doi: 10.1097/01.RVI.0000129915.48500.DC.
Results Reference
background
PubMed Identifier
17533532
Citation
Rajan DK, Saluja JS. Use of nitinol stents following recanalization of central venous occlusions in hemodialysis patients. Cardiovasc Intervent Radiol. 2007 Jul-Aug;30(4):662-7. doi: 10.1007/s00270-007-9083-9.
Results Reference
background
PubMed Identifier
18256373
Citation
Chan MR, Bedi S, Sanchez RJ, Young HN, Becker YT, Kellerman PS, Yevzlin AS. Stent placement versus angioplasty improves patency of arteriovenous grafts and blood flow of arteriovenous fistulae. Clin J Am Soc Nephrol. 2008 May;3(3):699-705. doi: 10.2215/CJN.04831107. Epub 2008 Feb 6.
Results Reference
background
PubMed Identifier
15671353
Citation
Pan HB, Liang HL, Lin YH, Chung HM, Wu TH, Chen CY, Fang HC, Chen CK, Lai PH, Yang CF. Metallic stent placement for treating peripheral outflow lesions in native arteriovenous fistula hemodialysis patients after insufficient balloon dilatation. AJR Am J Roentgenol. 2005 Feb;184(2):403-9. doi: 10.2214/ajr.184.2.01840403.
Results Reference
background
PubMed Identifier
18829240
Citation
Shemesh D, Goldin I, Zaghal I, Berlowitz D, Raveh D, Olsha O. Angioplasty with stent graft versus bare stent for recurrent cephalic arch stenosis in autogenous arteriovenous access for hemodialysis: a prospective randomized clinical trial. J Vasc Surg. 2008 Dec;48(6):1524-31, 1531.e1-2. doi: 10.1016/j.jvs.2008.07.071. Epub 2008 Oct 1.
Results Reference
background
PubMed Identifier
16959720
Citation
Naoum JJ, Irwin C, Hunter GC. The use of covered nitinol stents to salvage dialysis grafts after multiple failures. Vasc Endovascular Surg. 2006 Aug-Sep;40(4):275-9. doi: 10.1177/1538574406291803.
Results Reference
background
PubMed Identifier
18503914
Citation
Gupta M, Rajan DK, Tan KT, Sniderman KW, Simons ME. Use of expanded polytetrafluoroethylene-covered nitinol stents for the salvage of dysfunctional autogenous hemodialysis fistulas. J Vasc Interv Radiol. 2008 Jun;19(6):950-4. doi: 10.1016/j.jvir.2008.03.016. Epub 2008 Apr 28.
Results Reference
background
PubMed Identifier
14717801
Citation
Clark TW, Rajan DK. Treating intractable venous stenosis: present and future therapy. Semin Dial. 2004 Jan-Feb;17(1):4-8. doi: 10.1111/j.1525-139x.2004.17103.x.
Results Reference
background
PubMed Identifier
9867326
Citation
Yuan JG, Ohki T, Marin ML, Quintos RT, Krohn DL, Beitler JJ, Veith FJ. The effect of nonporous PTFE-covered stents on intimal hyperplasia following balloon arterial injury in minipigs. J Endovasc Surg. 1998 Nov;5(4):349-58. doi: 10.1583/1074-6218(1998)0052.0.CO;2.
Results Reference
background
PubMed Identifier
9234140
Citation
Fontaine AB, Dos Passos S, Spigos D, Cearlock J, Urbaneja A. Use of polyetherurethane to improve the biocompatibility of vascular stents. J Endovasc Surg. 1995 Aug;2(3):255-65. doi: 10.1583/1074-6218(1995)0022.0.CO;2.
Results Reference
background
Links:
URL
http://www.nlm.nih.gov/medlineplus/angioplasty.html
Description
Angioplasty
URL
http://www.nlm.nih.gov/medlineplus/dialysis.html
Description
Dialysis
URL
http://www.nlm.nih.gov/medlineplus/fistulas.html
Description
Fistulas
URL
http://www.nlm.nih.gov/medlineplus/kidneyfailure.html
Description
Kidney Failure
URL
http://druginfo.nlm.nih.gov/drugportal/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=drugportal&actionHandle=default&nextPage=jsp/drugportal/ResultScreen.jsp&TXTSUPERLISTID=0009005496&QV1=HEPARIN
Description
Heparin

Learn more about this trial

Placement of Covered Stents to Treat Hemodialysis Access Stenoses in the Cephalic Arch and Central Veins

We'll reach out to this number within 24 hrs